Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Stempoint Capital LP

Stempoint Capital LP boosted its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 22.1% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 72,577 shares of the company’s stock after purchasing an additional 13,147 shares during the quarter. Protagonist Therapeutics comprises 1.5% of Stempoint Capital LP’s holdings, making the stock its 26th biggest position. Stempoint Capital LP’s holdings in Protagonist Therapeutics were worth $7,650,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Royal Bank of Canada increased its stake in shares of Protagonist Therapeutics by 30.6% in the first quarter. Royal Bank of Canada now owns 9,964 shares of the company’s stock valued at $482,000 after purchasing an additional 2,334 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Protagonist Therapeutics by 0.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock worth $1,810,000 after buying an additional 348 shares during the period. Millennium Management LLC grew its holdings in Protagonist Therapeutics by 283.6% in the 1st quarter. Millennium Management LLC now owns 134,269 shares of the company’s stock worth $6,493,000 after buying an additional 99,269 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new position in Protagonist Therapeutics in the 2nd quarter worth approximately $987,000. Finally, Guggenheim Capital LLC increased its position in Protagonist Therapeutics by 1.6% in the 2nd quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock valued at $1,062,000 after acquiring an additional 303 shares during the period. 98.63% of the stock is owned by institutional investors and hedge funds.

Protagonist Therapeutics Price Performance

Shares of PTGX opened at $133.00 on Thursday. The firm’s 50 day moving average is $118.90 and its 200-day moving average is $102.59. The stock has a market capitalization of $8.55 billion, a P/E ratio of -73.48 and a beta of 1.79. Protagonist Therapeutics, Inc. has a 12-month low of $50.49 and a 12-month high of $143.29.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.50) by $0.55. The business had revenue of $56.37 million during the quarter, compared to analyst estimates of $11.70 million. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. As a group, equities research analysts forecast that Protagonist Therapeutics, Inc. will post 3.69 EPS for the current fiscal year.

Insider Buying and Selling at Protagonist Therapeutics

In other news, Director William D. Waddill sold 9,000 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the completion of the sale, the director directly owned 7,825 shares of the company’s stock, valued at $922,880.50. This trade represents a 53.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 75,000 shares of Protagonist Therapeutics stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $100.12, for a total value of $7,509,000.00. Following the completion of the transaction, the chief executive officer owned 523,478 shares in the company, valued at $52,410,617.36. The trade was a 12.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 161,130 shares of company stock valued at $16,355,220. Corporate insiders own 5.19% of the company’s stock.

Analyst Ratings Changes

PTGX has been the topic of several recent analyst reports. Johnson Rice set a $165.00 target price on Protagonist Therapeutics in a research note on Friday, July 17th. Citigroup reissued an “outperform” rating on shares of Protagonist Therapeutics in a research note on Friday, July 17th. Barclays raised their price target on Protagonist Therapeutics from $119.00 to $151.00 and gave the company an “overweight” rating in a report on Tuesday, July 14th. Wedbush lifted their price objective on shares of Protagonist Therapeutics from $112.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen raised shares of Protagonist Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 25th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $123.00.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.